Choisissez votre pays / Select your country

Ninalia NIPT The prenatal trisomy screening test based on maternal blood sample

Eurofins Biomnis and Non-Invasive Prenatal screening Test for trisomies 13, 18 and 21 (NIPT)

NIPT is an innovative genetic screening test for detecting the main fetal aneuploidies like Patau syndrome (trisomy 13), Edwards’ syndrome (trisomy 18) or Down syndrome (trisomy 21) in pregnant women at risk from these pathologies.

NEW

Today, this test also makes it possible to screen for other rarer chromosome abnormalities : autosomal abnormalities, deletions and duplications greater than 7 megabases (karyotype-equivalent resolution)

Several test options available:

  • Trisomies 21, 18 and 13
  • Trisomies 21, 18 and 13
    + autosomal aneuploidies
    + chromosomal imbalances greater than 7 megabases

According to local regulation, the test also provides optional fetal gender and sex chromosomes aneuploidies.

The non-invasive screening test uses cell-free DNA thanks to a sampling of maternal blood. It is without risk to foetus.

The non-invasive screening test has much greater sensitivity and specificity than serum marker screening.

Although NIPT is really sensitive and specific, it is classified as a screening option for women at increased risk of trisomies 13, 18 or 21. In case of positive result, an invasive diagnostic procedure such as amniocentesis will confirm the diagnosis.

In many cases, NIPT means that invasive sampling can be dispensed with, thus reducing the associated risk of losing the foetus.*

Eurofins Biomnis follows the International recommendations of the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal–Fetal Medicine (SMFM).

Geneticists who are qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to you as the prescriber to provide the best possible support in the implementation of this genetic test.

Advantages of Ninalia NIPT by Eurofins Biomnis

99 % Detection rateof Ninalia NIPT 1 Single blood sample 10 Available from 10 weeks (gestational age) 5 Results availablewithin 5 business days 95 % Can minimize unnecessary invasive sampling by 95%

Know more on Eurofins Biomnis expertise in foetal biochemistry and prenatal diagnostics.

Maternal Serum Markers (MSM) Karyotype
SNPs Array
 Pre-eclampsia

* Non-invasive prenatal testing of trisomies 13, 18 and 21 could make 95% of invasive tests, with an associated risk of miscarriage of around 0.5 to 1%, redundant (source: French National College of Gynaecologists and Obstetricians (CNGOF).

Eurofins Biomnis and NIPT Eurofins Biomnis and Non-Invasive Prenatal screening Test for trisomies 13, 18 and 21 (NIPT)

Vous avez refusé de partager votre position.
Désolé. Nous n'arrivons pas à savoir où vous êtes...
Il faut nous autoriser à voir votre position...
Votre navigateur ne possède pas cette fonctionnalité.

Partner laboratories

out of laboratories in total out of laboratories in total